Targeting KRAS in Lung Cancer: Spotlight on G12D

“Widely anticipated and incredibly promising” preliminary findings from a phase I study presented at the 2025 AACR Annual Meeting showed that the drug zoldonrasib, which targets active KRASG12D, is safe and has encouraging efficacy in patients with non–small cell lung cancer. “Clinical responses in over half of the patients is impressive,” said Robert H. Vonderheide, MD, DPhil, director of the Abramson Cancer Center, who was not involved in the study.